OVID - Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023) | Benzinga
- Posters with new preclinical data on the pharmacokinetic and pharmacodynamic behavior of OV329 support its profile as a potential best-in-class GABA aminotransferase inhibitor
- Disease models provide further evidence characterizing OV350 and its anticipated seizure reduction and neuroprotective profile, including its ability to reverse diazepam-resistant seizures
NEW YORK, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that five posters featuring data supporting its OV329 and OV350 programs for the potential treatment of epilepsies and treatment-resistant seizures will be presented at the 2023 American Epilepsy Society (AES) Annual Meeting in Orlando, Florida.
"We believe that new findings describing the pharmacokinetic and pharmacodynamic behavior of OV329 reinforce that it has a unique profile relative to prior GABA-aminotransferase inhibitors," said Manoj Malhotra, M.D. and Chief Medical Officer of Ovid Therapeutics. "GABA-AT is a validated target in seizure reduction that has been limited in clinical use to date. We hope to develop an improved, best-in-class GABA-AT inhibitor to treat patients suffering from pharmaco-resistant seizures."
"We are additionally excited to present multiple refractory seizure models evaluating OV350, a direct KCC2 transporter activator, which suggests its potential properties as a monotherapy as well as a potentiator of benzodiazepines," said Malhotra. "KCC2 is a novel mechanism of action which we believe has significant promise for the treatment of seizures."
Posters to be presented on Ovid development programs are listed here:
OV329, A POTENTIAL NEXT-GENERATION GABA-AT INHIBITOR
Title: Evaluation of OV329, a Next-Generation GABA-AT Inhibitor, in the Intra-Amygdala Kainate Model of Mesial Temporal Lobe Epilepsy.
Session Date & Time: 12-2 p.m. EST, Sunday, December 3
Presenter: Patrick Sarmiere, Ph.D.
Poster Number: #2.252
Title: Blocking of GABA-AT Activity by OV329 Selectively ...